Lancet Regional Health-Europe最新文献

{"title":"Preparing Europe for Recurrent Autochthonous Dengue Transmission: Public Health Implications and Preparedness Priorities","authors":"Giuseppe Ippolito, Alimuddin Zumla","doi":"10.1016/j.lanepe.2026.101758","DOIUrl":"10.1016/j.lanepe.2026.101758","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"66 ","pages":"Article 101758"},"PeriodicalIF":15.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13320452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148370902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficiency of peanut oral immunotherapy in preschool children with slow up-dosing and low maintenance dosing: a randomised controlled trial","authors":"Susanna Klevebro, Carina Uhl, Jon Roald Konradsen, Josefin Ullberg, Sandra Ganrud Tedner, Idun Holmdahl, Isabella Badolati, Rui Da Silva Rodrigues, Eva Sverremark-Ekström, Caroline Nilsson, Anna Asarnoj","doi":"10.1016/j.lanepe.2026.101690","DOIUrl":"10.1016/j.lanepe.2026.101690","url":null,"abstract":"<div><h3>Background</h3><div>Oral immunotherapy (OIT) is an emerging treatment for peanut allergy. A variety of protocols have been investigated, and accumulating evidence suggests that younger children may benefit from greater immune plasticity. The aim of the Small Children Oral Immunotherapy (SMACHO) study was to investigate the efficacy and safety of 3 years of peanut OIT with slow up-dosing and a low maintenance dose followed by 4–6 weeks of peanut-free diet in peanut-allergic toddlers.</div></div><div><h3>Methods</h3><div>SMACHO is an open-labelled randomised controlled trial in Stockholm, Sweden (NCT04511494). After a positive peanut challenge to a cumulative dose of maximum 278 mg peanut protein, 75 allergic children, aged 1–3 years, were randomised 2:1 to peanut OIT, with slow up-dosing every 4–6 weeks and a low maintenance dose of 285 mg peanut protein, or to avoidance. Primary outcome was the proportion of children achieving sustained unresponsiveness, defined as tolerating a cumulative dose of ≥750 mg peanut protein in a challenge after 3 years of OIT followed by 4–6 weeks of a peanut-free diet.</div></div><div><h3>Findings</h3><div>After OIT, 82% (41 of 50) achieved sustained unresponsiveness to a cumulative dose of ≥750 mg peanut protein. Before the peanut-free period, 84% (42 of 50) tolerated ≥750 mg peanut protein, compared with 3 of 25 children (12%) without treatment: difference 72% (95% confidence interval (CI) 56–88), p < 0·0001. Median cumulative tolerated dose after treatment was 5000 mg peanut protein compared with 3 mg after 3 years of peanut avoidance: difference 4997 mg (95% CI 4867–5127), p < 0·0001. Adverse events occurred in 0·7% of administered peanut doses, and most were mild. Six children reported eight severe dose-related events, with affected breathing, affected general well-being, or anaphylaxis. Epinephrine was administered at home three times in two children for dose-related reactions, all during up-dosing.</div></div><div><h3>Interpretation</h3><div>Peanut OIT for young children, using slow up-dosing and a low maintenance dose, may be safer than protocols that escalate more rapidly or involve a higher maintenance dose. Our protocol can be implemented in clinical practice. When combined with early dietary introduction of peanut; this strategy has potential to contribute to a future decline in the prevalence of peanut allergy.</div></div><div><h3>Funding</h3><div>This work was supported by a private non-commercial donation through Karolinska Institutet. Additionally by the Swedish Asthma and Allergy Association's Research Foundation; the Ellen, Walter and Lennart Hesselman Foundation for Scientific Research; Karolinska Institutet; Region Stockholm (ALF (FoUI-961605 and FoUI-973325) and clinical research appointments for Asarnoj, Nilsson, Konradsen and Klevebro); HRH Crown Princess Lovisa's association for child healthcare; the Samariten foundation for paediatric research; the Swedish Association for Aller","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"66 ","pages":"Article 101690"},"PeriodicalIF":15.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13330259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three Decades of Hantavirus Management in Chile: Lessons for Europe","authors":"Nicole Le Corre, Constanza Martínez-Valdebenito, Carolina Henriquez, Jenniffer Angulo, Marco Acuña, Cecilia Vial, Pablo A. Vial, Gregory Mertz, Marcela Ferrés","doi":"10.1016/j.lanepe.2026.101760","DOIUrl":"10.1016/j.lanepe.2026.101760","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"66 ","pages":"Article 101760"},"PeriodicalIF":15.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148310502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Toxicity Associated with Cancer Drug Approvals in Switzerland: International Implications","authors":"Ariadna Tibau, Aaron S. Kesselheim, Thomas J. Hwang","doi":"10.1016/j.lanepe.2026.101748","DOIUrl":"10.1016/j.lanepe.2026.101748","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"66 ","pages":"Article 101748"},"PeriodicalIF":15.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13312481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148354729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards HPV-Based Cervical Cancer Screening in Poland: Lessons From a Landmark Trial","authors":"Artur J. Jakimiuk, Marcin Januszewski","doi":"10.1016/j.lanepe.2026.101752","DOIUrl":"10.1016/j.lanepe.2026.101752","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"66 ","pages":"Article 101752"},"PeriodicalIF":15.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13315449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148363735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eastern Europe's alcohol-related liver disease crisis is preventable","authors":"The Lancet Regional Health – Europe","doi":"10.1016/j.lanepe.2026.101742","DOIUrl":"10.1016/j.lanepe.2026.101742","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"65 ","pages":"Article 101742"},"PeriodicalIF":13.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"European Congress of Endocrinology (ECE) 2026","authors":"Ivana Nedic","doi":"10.1016/j.lanepe.2026.101735","DOIUrl":"10.1016/j.lanepe.2026.101735","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"65 ","pages":"Article 101735"},"PeriodicalIF":13.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ending the Chronic Liver Disease Public Health Threat: Systemic Challenges Through the Patient Lens","authors":"Jeff J. McIntyre , Gina Bartes , Raquel Peck","doi":"10.1016/j.lanepe.2026.101731","DOIUrl":"10.1016/j.lanepe.2026.101731","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"65 ","pages":"Article 101731"},"PeriodicalIF":13.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Europe's policy readiness to confront the MASLD/MASH public health threat","authors":"Jeffrey V. Lazarus ,&nbsp;Trenton M. White ,&nbsp;Leire Agirre-Garrido ,&nbsp;Kushala W.M. Abeysekera ,&nbsp;Paul N. Brennan ,&nbsp;Radan Brůha ,&nbsp;Stefan Buttigieg ,&nbsp;Patrizia Carrieri ,&nbsp;Helena Cortez-Pinto ,&nbsp;Robert Flisiak ,&nbsp;Sven M.A. Francque ,&nbsp;Gema Frühbeck ,&nbsp;Liliana Simona Gheorghe ,&nbsp;Hannes Hagström ,&nbsp;Adriaan G. Holleboom ,&nbsp;Krasen Ivanov ,&nbsp;Mojca Jensterle ,&nbsp;Peter Jepsen ,&nbsp;Juozas Kupčinskas ,&nbsp;Henry E. Mark ,&nbsp;Andrew Yeoman","doi":"10.1016/j.lanepe.2026.101713","DOIUrl":"10.1016/j.lanepe.2026.101713","url":null,"abstract":"<div><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a public health threat in Europe. With an estimated 30.4% prevalence among the adult population in the European Union and United Kingdom, it is the most common chronic liver disease and is closely linked to obesity and type 2 diabetes, which can be considered as indicator conditions. Despite the scale of the burden, the spectrum of MASLD, including its advanced form, metabolic dysfunction-associated steatohepatitis (MASH), is weakly represented—or even absent—from health policy and development agendas. Further, the extent to which regional and national clinical practice guidelines (CPGs) on other liver diseases and related fields incorporate information on MASLD/MASH prevention or management is unclear. In this Series paper, we reviewed policy attention to MASLD/MASH across the European Union and the United Kingdom. We report low policy readiness across European countries to address MASLD/MASH. Only two (7.1%), Romania and Sweden, had a subnational strategy, while 13 (46.4%) referenced MASLD/MASH in other national or subnational action plans, predominantly those for liver disease and obesity. No country included MASLD/MASH in its priority non-communicable disease list. Additionally, 15 (53.6%) countries had national MASLD/MASH CPGs, while 25 (89.3%) mentioned MASLD/MASH in other national CPGs, most often those for obesity, diabetes, cirrhosis, liver transplantation, and primary care, respectively. We conclude that MASLD/MASH remains insufficiently addressed from a policy perspective, which contributes to low readiness to address this public health threat.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"65 ","pages":"Article 101713"},"PeriodicalIF":13.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease","authors":"Nicola Pugliese ,&nbsp;Trenton M. White ,&nbsp;Paul N. Brennan ,&nbsp;Silvana Pannain ,&nbsp;Hannes Hagström ,&nbsp;Maurice Michel ,&nbsp;Lisa Rice-Duek ,&nbsp;Giovanni Targher ,&nbsp;Cyrielle Caussy ,&nbsp;John F. Dillon ,&nbsp;Frank Tacke ,&nbsp;Christopher J. Kopka ,&nbsp;Giada Sebastiani ,&nbsp;Jerome Boursier ,&nbsp;Emmanuel A. Tsochatzis ,&nbsp;Willem Pieter Brouwer ,&nbsp;Giovanni Guaraldi ,&nbsp;Roberto Vettor ,&nbsp;Maja Thiele ,&nbsp;Michael Roden ,&nbsp;Jeffrey V. Lazarus","doi":"10.1016/j.lanepe.2026.101722","DOIUrl":"10.1016/j.lanepe.2026.101722","url":null,"abstract":"<div><div>Steatotic liver disease (SLD) is the leading cause of chronic liver disease in Europe, with liver fibrosis representing the strongest predictor of liver-related outcomes and an important contributor to cardiometabolic risk. This Series paper examines diagnostic innovation and models of care to improve fibrosis detection and risk stratification across the continuum of care for SLD. A growing range of non-invasive tests for fibrosis assessment is now available, including blood-based biomarkers, imaging modalities, automated laboratory algorithms, and artificial intelligence-enabled tools. However, implementation remains inconsistent because of limited awareness, restricted geographic and financial access to advanced diagnostics, fragmented referral pathways, heterogeneous reimbursement, limited use of automated reflex testing, and poor digital integration across laboratories and electronic health records. Integrated multidisciplinary models of care linking primary care with specialist services may improve early fibrosis detection, referral efficiency, and equitable access to risk-stratified management, particularly among people living with indicator conditions such as type 2 diabetes and obesity.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"65 ","pages":"Article 101722"},"PeriodicalIF":13.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}